leisure time -WSS

leisure time

author：comprehensive 2025-10-01 16:38:27 - browse：6

Element Biosciences exterior -- biotech coverage from STAT — Element Biosciences exterior Element Biosciences

SAN DIEGO — Companies racing to read the genome accurately, quickly, and affordably have hit a snag recently, with several firms reporting that their growth has slowed, stalled, or reversed. Upstart Element Biosciences is hoping it can succeed despite the challenging market conditions.

The San Diego firm launched a $290,000 sequencer, dubbed Aviti, in March 2022 and now has 150 instruments installed in more than 25 countries, according to a sales update Element shared with STAT. The modest growth comes at a time when some other players are struggling. Singular Genomics announced layoffs of 20% of its workforce earlier this year after the lackluster launch of its own sequencer. And Pacific Biosciences recently laid off nearly 200 employees after reporting disappointing first-quarter sales.

Element still has a long way to go in its bid to rival Illumina, a genomics giant that dominates 80% of the sequencing market and has more than 23,000 instruments in use around the world. That includes the NextSeq 2000, a $335,000 sequencer with a similar output to Aviti. Element is betting its blend of accuracy and a more moderate price point can help it carve out a niche of academic and biopharma customers.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Van's Gluten Free Original Waffles recalled for possible wheat allergen

WSS

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

Dairy farmers resist CDC push for PPE against bird flu virus

Grail is spending more than ever lobbying Congress

These geoengineering technologies could help combat the climate crisis, scientists say

Inside the fall of star MIT scientist David Sabatini

Readout LOUD podcast: brain research, obesity drug sales, Novartis

knowledge

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

leisure time

BioMarin wins approval for gene therapy to treat hemophilia A

Meta looks to target Twitter with a rival app called Threads

Psychedelics group wrestles with new pharma identity

Software glitch causes Tandem insulin pump to shutdown, FDA warns

Cancer drug shortages should be causing more outrage

Telehealth startups turn to complex chronic diseases

23andMe had bad news about my health. I wish a person had delivered it

Readout Newsletter: Sanofi, Novavax, Maze x Shionogi news

Anesthesiologist group: stop taking Ozempic before surgery

H5N1 bird flu: what we're starting to learn about infection in cows

hotspot

Readout LOUD podcast: What to know about H5N1 bird flu

PhRMA sues HHS over Medicare drug price negotiation

Making AI in medicine accessible to smaller, and rural hospitals

CDC wastewater surveillance dashboard to track bird flu hotspots

Duchenne patients, backed by ‘dark money’ group, to debate drug prices

Community addresses injustice for Long Island mothers

leisure time

focus

hotspot

explore